Another advantage of TDO/IDO inhibition in cancer therapy is that of the resultant elevation of tumoral [Trp] blocking Trp transport into tumours and enhancing T-cell immune function and anti-tumour activity. This evidence concerns the gene IDO1 and neoplasm.